Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer
Hepcidin and ferroportin, which are known as key iron regulators, may be used in future treatments of pancreatic ductal adenocarcinoma. Iron is essential for life support; it helps oxygen molecules bind to hemoglobin and acts as an important catalytic enzyme center. However, iron overload is a risk...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2018-05, Vol.15 (5), p.8125-8133 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8133 |
|---|---|
| container_issue | 5 |
| container_start_page | 8125 |
| container_title | Oncology letters |
| container_volume | 15 |
| creator | Toshiyama, Reishi Konno, Masamitsu Eguchi, Hidetoshi Asai, Ayumu Noda, Takehiro Koseki, Jun Asukai, Kei Ohashi, Tomofumi Matsushita, Katsunori Iwagami, Yoshifumi Yamada, Daisaku Asaoka, Tadafumi Wada, Hiroshi Kawamoto, Koichi Gotoh, Kunihito Kudo, Toshihiro Satoh, Taroh Doki, Yuichiro Mori, Masaki Ishii, Hideshi |
| description | Hepcidin and ferroportin, which are known as key iron regulators, may be used in future treatments of pancreatic ductal adenocarcinoma. Iron is essential for life support; it helps oxygen molecules bind to hemoglobin and acts as an important catalytic enzyme center. However, iron overload is a risk factor for cancer, possibly through the generation of reactive oxygen species (ROS). Hepcidin, which is a peptide hormone mainly generated by the liver, inhibits iron absorption via enterocytes and iron release from macrophages. Notably, hepcidin regulates iron homeostasis in the body by regulating the iron transporter ferroportin. In the present study, it was assumed that high hepcidin expression and low ferroportin expression result in malignancy. Therefore, it was examined whether hepcidin and ferroportin expression levels were correlated with the prognosis of pancreatic cancer in patients. Results revealed that high hepcidin expression levels and low ferroportin expression levels in pancreatic cancer tissue were significantly associated with poor prognosis in the analyses of overall survival (P=0.0140 and 0.0478, respectively). Additionally, there was no significant difference in disease-free survival in the hepcidin- and ferroportin-staining groups. Hepcidin expression correlated with the pathological stage and vascular invasion (P=0.0493 and 0.0400, respectively), and ferroportin expression was correlated with age (P=0.0372). Multivariate analysis of overall survival in the hepcidin-staining group revealed that pathological N factor (pN), adjuvant chemotherapy, and hepcidin expression were independent prognostic factors (P=0.0450, 0.0002, and 0.0049, respectively). Similarly, multivariate analysis of overall survival in the ferroportin-staining group revealed that vascular invasion, and ferroportin expression were independent prognostic factors (P=0.0028, P |
| doi_str_mv | 10.3892/ol.2018.8357 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5921263</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A542804026</galeid><sourcerecordid>A542804026</sourcerecordid><originalsourceid>FETCH-LOGICAL-c510t-fa2022a519662b3b874f03d904ddc89673e0753975e8b8107573823eadf5564b3</originalsourceid><addsrcrecordid>eNptkk1v1DAQhi0EotXSG2dkCQn10N36I06cC9KqooBUiUs5W44z2bhy7GAnhfbX46jL0kXYB1vjZ157xi9CbynZcFmzy-A2jFC5kVxUL9AprWq2pkSyl4d9VZygs5TuSB6ipFKWr9EJqytOa0ZO0bxNKRirJxs8Dh22Ma8DTLoJzhoM_vFhANzDaGxrPYZfY4SUFtjBPbiEf9qpx1MPeIxh50OyaZEZsyD4aX88am8i5JDBJm8hvkGvOu0SnO3XFfp-_en26sv65tvnr1fbm7URlEzrTjPCmBa0LkvW8EZWRUd4W5OibY2sy4oDqQSvKwGykblWUXHJOOi2E6IsGr5CH590x7kZoDX5SVE7NUY76Piggrbq-MTbXu3CvRI1o6zkWeB8LxDDjxnSpAabDDinPYQ5KUZy40kpyYK-_we9C3P0ubxMFYwKSSj9S-20A2V9F_K9ZhFVW1EwSQqS712hzX-oPFsYrAkeOpvjRwkfniX0oN3Up-Dm5VvTMXjxBJoYUorQHZpBiVospYJTi6XUYqmMv3vewAP8x0D8N-LXxdA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2042158011</pqid></control><display><type>article</type><title>Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer</title><source>Spandidos Publications Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Toshiyama, Reishi ; Konno, Masamitsu ; Eguchi, Hidetoshi ; Asai, Ayumu ; Noda, Takehiro ; Koseki, Jun ; Asukai, Kei ; Ohashi, Tomofumi ; Matsushita, Katsunori ; Iwagami, Yoshifumi ; Yamada, Daisaku ; Asaoka, Tadafumi ; Wada, Hiroshi ; Kawamoto, Koichi ; Gotoh, Kunihito ; Kudo, Toshihiro ; Satoh, Taroh ; Doki, Yuichiro ; Mori, Masaki ; Ishii, Hideshi</creator><creatorcontrib>Toshiyama, Reishi ; Konno, Masamitsu ; Eguchi, Hidetoshi ; Asai, Ayumu ; Noda, Takehiro ; Koseki, Jun ; Asukai, Kei ; Ohashi, Tomofumi ; Matsushita, Katsunori ; Iwagami, Yoshifumi ; Yamada, Daisaku ; Asaoka, Tadafumi ; Wada, Hiroshi ; Kawamoto, Koichi ; Gotoh, Kunihito ; Kudo, Toshihiro ; Satoh, Taroh ; Doki, Yuichiro ; Mori, Masaki ; Ishii, Hideshi</creatorcontrib><description>Hepcidin and ferroportin, which are known as key iron regulators, may be used in future treatments of pancreatic ductal adenocarcinoma. Iron is essential for life support; it helps oxygen molecules bind to hemoglobin and acts as an important catalytic enzyme center. However, iron overload is a risk factor for cancer, possibly through the generation of reactive oxygen species (ROS). Hepcidin, which is a peptide hormone mainly generated by the liver, inhibits iron absorption via enterocytes and iron release from macrophages. Notably, hepcidin regulates iron homeostasis in the body by regulating the iron transporter ferroportin. In the present study, it was assumed that high hepcidin expression and low ferroportin expression result in malignancy. Therefore, it was examined whether hepcidin and ferroportin expression levels were correlated with the prognosis of pancreatic cancer in patients. Results revealed that high hepcidin expression levels and low ferroportin expression levels in pancreatic cancer tissue were significantly associated with poor prognosis in the analyses of overall survival (P=0.0140 and 0.0478, respectively). Additionally, there was no significant difference in disease-free survival in the hepcidin- and ferroportin-staining groups. Hepcidin expression correlated with the pathological stage and vascular invasion (P=0.0493 and 0.0400, respectively), and ferroportin expression was correlated with age (P=0.0372). Multivariate analysis of overall survival in the hepcidin-staining group revealed that pathological N factor (pN), adjuvant chemotherapy, and hepcidin expression were independent prognostic factors (P=0.0450, 0.0002, and 0.0049, respectively). Similarly, multivariate analysis of overall survival in the ferroportin-staining group revealed that vascular invasion, and ferroportin expression were independent prognostic factors (P=0.0028, P<0.0001, and P=0.0056, respectively). Thus, hepcidin and ferroportin expressions might be novel prognostic indicators for pancreatic cancer.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2018.8357</identifier><identifier>PMID: 29731920</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Care and treatment ; Cell growth ; Chemotherapy ; Confidence intervals ; Development and progression ; Enzymes ; Gene expression ; Genetic aspects ; Health aspects ; Iron ; Medical prognosis ; Metabolism ; Nutrient interactions ; Oncology ; Pancreatic cancer ; Peptide hormones ; Reactive oxygen species ; Regression analysis ; Surgery ; Tumors</subject><ispartof>Oncology letters, 2018-05, Vol.15 (5), p.8125-8133</ispartof><rights>COPYRIGHT 2018 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2018</rights><rights>Copyright © 2018, Spandidos Publications 2018</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c510t-fa2022a519662b3b874f03d904ddc89673e0753975e8b8107573823eadf5564b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921263/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921263/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,725,778,782,883,27907,27908,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29731920$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Toshiyama, Reishi</creatorcontrib><creatorcontrib>Konno, Masamitsu</creatorcontrib><creatorcontrib>Eguchi, Hidetoshi</creatorcontrib><creatorcontrib>Asai, Ayumu</creatorcontrib><creatorcontrib>Noda, Takehiro</creatorcontrib><creatorcontrib>Koseki, Jun</creatorcontrib><creatorcontrib>Asukai, Kei</creatorcontrib><creatorcontrib>Ohashi, Tomofumi</creatorcontrib><creatorcontrib>Matsushita, Katsunori</creatorcontrib><creatorcontrib>Iwagami, Yoshifumi</creatorcontrib><creatorcontrib>Yamada, Daisaku</creatorcontrib><creatorcontrib>Asaoka, Tadafumi</creatorcontrib><creatorcontrib>Wada, Hiroshi</creatorcontrib><creatorcontrib>Kawamoto, Koichi</creatorcontrib><creatorcontrib>Gotoh, Kunihito</creatorcontrib><creatorcontrib>Kudo, Toshihiro</creatorcontrib><creatorcontrib>Satoh, Taroh</creatorcontrib><creatorcontrib>Doki, Yuichiro</creatorcontrib><creatorcontrib>Mori, Masaki</creatorcontrib><creatorcontrib>Ishii, Hideshi</creatorcontrib><title>Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>Hepcidin and ferroportin, which are known as key iron regulators, may be used in future treatments of pancreatic ductal adenocarcinoma. Iron is essential for life support; it helps oxygen molecules bind to hemoglobin and acts as an important catalytic enzyme center. However, iron overload is a risk factor for cancer, possibly through the generation of reactive oxygen species (ROS). Hepcidin, which is a peptide hormone mainly generated by the liver, inhibits iron absorption via enterocytes and iron release from macrophages. Notably, hepcidin regulates iron homeostasis in the body by regulating the iron transporter ferroportin. In the present study, it was assumed that high hepcidin expression and low ferroportin expression result in malignancy. Therefore, it was examined whether hepcidin and ferroportin expression levels were correlated with the prognosis of pancreatic cancer in patients. Results revealed that high hepcidin expression levels and low ferroportin expression levels in pancreatic cancer tissue were significantly associated with poor prognosis in the analyses of overall survival (P=0.0140 and 0.0478, respectively). Additionally, there was no significant difference in disease-free survival in the hepcidin- and ferroportin-staining groups. Hepcidin expression correlated with the pathological stage and vascular invasion (P=0.0493 and 0.0400, respectively), and ferroportin expression was correlated with age (P=0.0372). Multivariate analysis of overall survival in the hepcidin-staining group revealed that pathological N factor (pN), adjuvant chemotherapy, and hepcidin expression were independent prognostic factors (P=0.0450, 0.0002, and 0.0049, respectively). Similarly, multivariate analysis of overall survival in the ferroportin-staining group revealed that vascular invasion, and ferroportin expression were independent prognostic factors (P=0.0028, P<0.0001, and P=0.0056, respectively). Thus, hepcidin and ferroportin expressions might be novel prognostic indicators for pancreatic cancer.</description><subject>Care and treatment</subject><subject>Cell growth</subject><subject>Chemotherapy</subject><subject>Confidence intervals</subject><subject>Development and progression</subject><subject>Enzymes</subject><subject>Gene expression</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Iron</subject><subject>Medical prognosis</subject><subject>Metabolism</subject><subject>Nutrient interactions</subject><subject>Oncology</subject><subject>Pancreatic cancer</subject><subject>Peptide hormones</subject><subject>Reactive oxygen species</subject><subject>Regression analysis</subject><subject>Surgery</subject><subject>Tumors</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkk1v1DAQhi0EotXSG2dkCQn10N36I06cC9KqooBUiUs5W44z2bhy7GAnhfbX46jL0kXYB1vjZ157xi9CbynZcFmzy-A2jFC5kVxUL9AprWq2pkSyl4d9VZygs5TuSB6ipFKWr9EJqytOa0ZO0bxNKRirJxs8Dh22Ma8DTLoJzhoM_vFhANzDaGxrPYZfY4SUFtjBPbiEf9qpx1MPeIxh50OyaZEZsyD4aX88am8i5JDBJm8hvkGvOu0SnO3XFfp-_en26sv65tvnr1fbm7URlEzrTjPCmBa0LkvW8EZWRUd4W5OibY2sy4oDqQSvKwGykblWUXHJOOi2E6IsGr5CH590x7kZoDX5SVE7NUY76Piggrbq-MTbXu3CvRI1o6zkWeB8LxDDjxnSpAabDDinPYQ5KUZy40kpyYK-_we9C3P0ubxMFYwKSSj9S-20A2V9F_K9ZhFVW1EwSQqS712hzX-oPFsYrAkeOpvjRwkfniX0oN3Up-Dm5VvTMXjxBJoYUorQHZpBiVospYJTi6XUYqmMv3vewAP8x0D8N-LXxdA</recordid><startdate>20180501</startdate><enddate>20180501</enddate><creator>Toshiyama, Reishi</creator><creator>Konno, Masamitsu</creator><creator>Eguchi, Hidetoshi</creator><creator>Asai, Ayumu</creator><creator>Noda, Takehiro</creator><creator>Koseki, Jun</creator><creator>Asukai, Kei</creator><creator>Ohashi, Tomofumi</creator><creator>Matsushita, Katsunori</creator><creator>Iwagami, Yoshifumi</creator><creator>Yamada, Daisaku</creator><creator>Asaoka, Tadafumi</creator><creator>Wada, Hiroshi</creator><creator>Kawamoto, Koichi</creator><creator>Gotoh, Kunihito</creator><creator>Kudo, Toshihiro</creator><creator>Satoh, Taroh</creator><creator>Doki, Yuichiro</creator><creator>Mori, Masaki</creator><creator>Ishii, Hideshi</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180501</creationdate><title>Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer</title><author>Toshiyama, Reishi ; Konno, Masamitsu ; Eguchi, Hidetoshi ; Asai, Ayumu ; Noda, Takehiro ; Koseki, Jun ; Asukai, Kei ; Ohashi, Tomofumi ; Matsushita, Katsunori ; Iwagami, Yoshifumi ; Yamada, Daisaku ; Asaoka, Tadafumi ; Wada, Hiroshi ; Kawamoto, Koichi ; Gotoh, Kunihito ; Kudo, Toshihiro ; Satoh, Taroh ; Doki, Yuichiro ; Mori, Masaki ; Ishii, Hideshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c510t-fa2022a519662b3b874f03d904ddc89673e0753975e8b8107573823eadf5564b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Care and treatment</topic><topic>Cell growth</topic><topic>Chemotherapy</topic><topic>Confidence intervals</topic><topic>Development and progression</topic><topic>Enzymes</topic><topic>Gene expression</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Iron</topic><topic>Medical prognosis</topic><topic>Metabolism</topic><topic>Nutrient interactions</topic><topic>Oncology</topic><topic>Pancreatic cancer</topic><topic>Peptide hormones</topic><topic>Reactive oxygen species</topic><topic>Regression analysis</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Toshiyama, Reishi</creatorcontrib><creatorcontrib>Konno, Masamitsu</creatorcontrib><creatorcontrib>Eguchi, Hidetoshi</creatorcontrib><creatorcontrib>Asai, Ayumu</creatorcontrib><creatorcontrib>Noda, Takehiro</creatorcontrib><creatorcontrib>Koseki, Jun</creatorcontrib><creatorcontrib>Asukai, Kei</creatorcontrib><creatorcontrib>Ohashi, Tomofumi</creatorcontrib><creatorcontrib>Matsushita, Katsunori</creatorcontrib><creatorcontrib>Iwagami, Yoshifumi</creatorcontrib><creatorcontrib>Yamada, Daisaku</creatorcontrib><creatorcontrib>Asaoka, Tadafumi</creatorcontrib><creatorcontrib>Wada, Hiroshi</creatorcontrib><creatorcontrib>Kawamoto, Koichi</creatorcontrib><creatorcontrib>Gotoh, Kunihito</creatorcontrib><creatorcontrib>Kudo, Toshihiro</creatorcontrib><creatorcontrib>Satoh, Taroh</creatorcontrib><creatorcontrib>Doki, Yuichiro</creatorcontrib><creatorcontrib>Mori, Masaki</creatorcontrib><creatorcontrib>Ishii, Hideshi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toshiyama, Reishi</au><au>Konno, Masamitsu</au><au>Eguchi, Hidetoshi</au><au>Asai, Ayumu</au><au>Noda, Takehiro</au><au>Koseki, Jun</au><au>Asukai, Kei</au><au>Ohashi, Tomofumi</au><au>Matsushita, Katsunori</au><au>Iwagami, Yoshifumi</au><au>Yamada, Daisaku</au><au>Asaoka, Tadafumi</au><au>Wada, Hiroshi</au><au>Kawamoto, Koichi</au><au>Gotoh, Kunihito</au><au>Kudo, Toshihiro</au><au>Satoh, Taroh</au><au>Doki, Yuichiro</au><au>Mori, Masaki</au><au>Ishii, Hideshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2018-05-01</date><risdate>2018</risdate><volume>15</volume><issue>5</issue><spage>8125</spage><epage>8133</epage><pages>8125-8133</pages><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>Hepcidin and ferroportin, which are known as key iron regulators, may be used in future treatments of pancreatic ductal adenocarcinoma. Iron is essential for life support; it helps oxygen molecules bind to hemoglobin and acts as an important catalytic enzyme center. However, iron overload is a risk factor for cancer, possibly through the generation of reactive oxygen species (ROS). Hepcidin, which is a peptide hormone mainly generated by the liver, inhibits iron absorption via enterocytes and iron release from macrophages. Notably, hepcidin regulates iron homeostasis in the body by regulating the iron transporter ferroportin. In the present study, it was assumed that high hepcidin expression and low ferroportin expression result in malignancy. Therefore, it was examined whether hepcidin and ferroportin expression levels were correlated with the prognosis of pancreatic cancer in patients. Results revealed that high hepcidin expression levels and low ferroportin expression levels in pancreatic cancer tissue were significantly associated with poor prognosis in the analyses of overall survival (P=0.0140 and 0.0478, respectively). Additionally, there was no significant difference in disease-free survival in the hepcidin- and ferroportin-staining groups. Hepcidin expression correlated with the pathological stage and vascular invasion (P=0.0493 and 0.0400, respectively), and ferroportin expression was correlated with age (P=0.0372). Multivariate analysis of overall survival in the hepcidin-staining group revealed that pathological N factor (pN), adjuvant chemotherapy, and hepcidin expression were independent prognostic factors (P=0.0450, 0.0002, and 0.0049, respectively). Similarly, multivariate analysis of overall survival in the ferroportin-staining group revealed that vascular invasion, and ferroportin expression were independent prognostic factors (P=0.0028, P<0.0001, and P=0.0056, respectively). Thus, hepcidin and ferroportin expressions might be novel prognostic indicators for pancreatic cancer.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>29731920</pmid><doi>10.3892/ol.2018.8357</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2018-05, Vol.15 (5), p.8125-8133 |
| issn | 1792-1074 1792-1082 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5921263 |
| source | Spandidos Publications Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Care and treatment Cell growth Chemotherapy Confidence intervals Development and progression Enzymes Gene expression Genetic aspects Health aspects Iron Medical prognosis Metabolism Nutrient interactions Oncology Pancreatic cancer Peptide hormones Reactive oxygen species Regression analysis Surgery Tumors |
| title | Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T22%3A28%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20iron%20metabolic%20enzyme%20hepcidin%20expression%20levels%20with%20the%20prognosis%20of%20patients%20with%20pancreatic%20cancer&rft.jtitle=Oncology%20letters&rft.au=Toshiyama,%20Reishi&rft.date=2018-05-01&rft.volume=15&rft.issue=5&rft.spage=8125&rft.epage=8133&rft.pages=8125-8133&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2018.8357&rft_dat=%3Cgale_pubme%3EA542804026%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2042158011&rft_id=info:pmid/29731920&rft_galeid=A542804026&rfr_iscdi=true |